On October 17, Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that its innovative Class 1 national drug candidate, CS231295, for cancer treatment has received acceptance for its clinical trial application (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China (Acceptance Numbers: CXHL2401105, CXHL2401107, CXHL2401108).
Malignant tumors remain a leading cause of death worldwide. Despite significant advancements in clinical treatment, many tumors remain incurable, with drug resistance and recurrence posing major threats to long-term survival. Particularly challenging are malignant brain tumors and brain metastases, which not only directly endanger patients’ lives but also create natural barriers that hinder the effectiveness of drug therapies due to the blood-brain barrier. Thus, the development of novel anti-tumor drugs with brain-penetrating capabilities has become a crucial focus in enhancing current cancer treatment efficacy.
CS231295, a small-molecule, multi-target protein kinase inhibitor developed by Chipscreen, possesses proprietary intellectual property rights and demonstrates the ability to induce synthetic lethality in tumors with specific anti-cancer gene defects, offering targeted therapeutic effects and a new treatment option for these patients. Additionally, CS231295 exhibits significant anti-tumor angiogenesis properties, contributing to broad-spectrum anti-tumor activity. Whether used alone or in combination with other anti-cancer agents, it holds promise for delivering differentiated innovative treatment solutions for various tumors. With its favorable blood-brain barrier permeability, CS231295 shows notable therapeutic advantages for both primary and metastatic brain tumors, indicating strong potential in treating malignant brain tumors and brain metastases. Preclinical studies have already demonstrated its significant pharmacodynamic activity, ideal pharmacokinetic profile, and good safety profile.- Flcube.com
